Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) is a clinical-stage biopharmaceutical company focused on developing allogeneic T-cell immunotherapies targeting infectious diseases and oncology. The company completed its SPAC de-merger transaction and began trading publicly in early 2023, with its 10-Q for the quarter ended March 31, 2023 filed with the SEC on May 22, 2023 under accession number 0001410578-23-001349. As of that filing, TVGN was operating in the biotechnology and clinical-stage therapeutics sector, advancing its proprietary T-cell receptor platform. The company remains in the development stage with no approved products commercially available. Sign up for SpacDesk to access the full filing history, de-SPAC timeline, and analytics for TVGN and hundreds of other SPAC-linked equities.